Vilanterol

Summary

Vilanterol (CHEMBL1198857) is an approved small-molecule β-adrenergic agonist targeting ADRB2; indicated across 2 conditions including chronic obstructive pulmonary disease and asthma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (ADRB2)
• Indications: 2 conditions
• Clinical trials: 68
• Chemistry: 486.4 Da · C24H33Cl2NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1198857
Name	Vilanterol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10184665
ChEBI	CHEBI:75037
Molecular formula	C24H33Cl2NO5
Molecular weight	486.4
InChIKey	DAFYYTQWSAWIGS-DEOSSOPVSA-N

SMILES: C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNC[C@@H](C2=CC(=C(C=C2)O)CO)O)Cl

IUPAC name: 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol

ChEBI definition: An dichlorobenzene derivative that is used in the form of its trifenate salt for treatment of chronic obstructive pulmonary disease.

Pharmacological roles (ChEBI): β-adrenergic agonist, bronchodilator agent.

Also known as: GW-642444, GW-642444X, GW642444, GW642444X, Vilanterol, VILANTEROL, Vilanterol (trifenatate), vilanterol

Parent form; salt/anhydrous children: CHEMBL1084647, CHEMBL1084172

Patent coverage: 912 distinct patent families (2,552 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,556 (61%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRB2	β2-adrenoceptor	Agonist	9.4	0.4%	P07550

Broader ChEMBL bioactivity targets: 17 (assay-derived). Sample: Sodium channel protein type 5 subunit alpha, D(1A) dopamine receptor, Beta-2 adrenergic receptor, Beta-1 adrenergic receptor, Motilin receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Prostaglandin G/H synthase 2, Sodium-dependent dopamine transporter, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Nuclear receptor subfamily 1 group I member 2, Growth hormone secretagogue receptor type 1, Melanocortin receptor 3, Bile salt export pump.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 17 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB2	8.24	AC50	5.8	nM	CHEMBL_ACT_25233752
ADRA1A	5.96	AC50	1100	nM	CHEMBL_ACT_25230096
DRD1	5.66	AC50	2200	nM	CHEMBL_ACT_25180871
SLC6A4	5.55	AC50	2800	nM	CHEMBL_ACT_25150684
SCN5A	5.3	AC50	5000	nM	CHEMBL_ACT_25158981
SLC6A3	5.17	AC50	6700	nM	CHEMBL_ACT_25124306
ADRB1	5	AC50	10000	nM	CHEMBL_ACT_25122125

Target pathways

Aggregated over 1 target gene(s): ADRB2.

Top Reactome pathways

16 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	ADRB2
Membrane Trafficking	1	ADRB2
Signaling by GPCR	1	ADRB2
Class A/1 (Rhodopsin-like receptors)	1	ADRB2
Amine ligand-binding receptors	1	ADRB2
GPCR downstream signalling	1	ADRB2
Adrenoceptors	1	ADRB2
Metabolism of proteins	1	ADRB2
G alpha (s) signalling events	1	ADRB2
GPCR ligand binding	1	ADRB2
Vesicle-mediated transport	1	ADRB2
Deubiquitination	1	ADRB2
Ub-specific processing proteases	1	ADRB2
Post-translational protein modification	1	ADRB2
Cargo recognition for clathrin-mediated endocytosis	1	ADRB2
Clathrin-mediated endocytosis	1	ADRB2

Dominant GO biological processes

GO term	Targets
diet induced thermogenesis	1
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure	1
regulation of sodium ion transport	1
transcription by RNA polymerase II	1
receptor-mediated endocytosis	1
smooth muscle contraction	1
cell surface receptor signaling pathway	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
endosome to lysosome transport	1
response to cold	1
positive regulation of cardiac muscle cell apoptotic process	1
negative regulation of cardiac muscle cell apoptotic process	1
positive regulation of bone mineralization	1
heat generation	1
negative regulation of multicellular organism growth	1

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
asthma	3	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 68.

Phase distribution

Phase	Trials
PHASE3	30
PHASE1	13
PHASE2	11
PHASE4	9
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06571942	PHASE4	RECRUITING	Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
NCT01957150	PHASE4	COMPLETED	Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
NCT02730351	PHASE4	COMPLETED	Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)
NCT03152149	PHASE4	COMPLETED	INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol
NCT03315000	PHASE4	COMPLETED	Effect of Vilanterol on Methacholine Challenge Results
NCT03363191	PHASE4	WITHDRAWN	The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
NCT03949842	PHASE4	WITHDRAWN	Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study
NCT04522596	PHASE4	UNKNOWN	Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure
NCT05342558	PHASE4	COMPLETED	Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.
NCT01181895	PHASE3	COMPLETED	Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
NCT01313637	PHASE3	COMPLETED	A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
NCT01313676	PHASE3	COMPLETED	Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
NCT01316887	PHASE3	COMPLETED	A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01316900	PHASE3	COMPLETED	24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
NCT01316913	PHASE3	COMPLETED	24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
NCT01323660	PHASE3	COMPLETED	An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
NCT01328444	PHASE3	COMPLETED	An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
NCT01336608	PHASE3	COMPLETED	A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
NCT01376245	PHASE3	COMPLETED	A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
NCT01498653	PHASE3	COMPLETED	Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry
NCT01627327	PHASE3	COMPLETED	Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
NCT01686633	PHASE3	COMPLETED	An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.
NCT01691885	PHASE3	COMPLETED	RELOVAIR® Lung Deflation Study
NCT01706198	PHASE3	COMPLETED	An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
NCT01716520	PHASE3	COMPLETED	Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
NCT01777334	PHASE3	COMPLETED	The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
NCT01817764	PHASE3	COMPLETED	A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01822899	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01899742	PHASE3	COMPLETED	The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
NCT02014480	PHASE3	COMPLETED	A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02094937	PHASE3	COMPLETED	A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects
NCT02105974	PHASE3	COMPLETED	Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02164513	PHASE3	COMPLETED	A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02301975	PHASE3	COMPLETED	An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma
NCT02446418	PHASE3	COMPLETED	A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
NCT02487446	PHASE3	COMPLETED	Efficacy and Safety Study of QVA149 in COPD Patients
NCT02487498	PHASE3	COMPLETED	Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
NCT03162055	PHASE3	COMPLETED	Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT04536675	PHASE3	UNKNOWN	Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery
NCT07282886	PHASE2	RECRUITING	VENTURI (VENTilation Using Respiratory Imaging)
NCT00347139	PHASE2	COMPLETED	Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients
NCT00354874	PHASE2	COMPLETED	Investigation Of A New Medication (GW642444) In Asthmatic Patients
NCT00372112	PHASE2	COMPLETED	A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00606684	PHASE2	COMPLETED	A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00731822	PHASE2	COMPLETED	A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)
NCT00749411	PHASE2	COMPLETED	Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
NCT01453023	PHASE2	COMPLETED	Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study
NCT01453296	PHASE2	COMPLETED	Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects
NCT01573767	PHASE2	COMPLETED	Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
NCT02570165	PHASE2	COMPLETED	Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00625196	PHASE1	COMPLETED	Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects
NCT00671216	PHASE1	COMPLETED	A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
NCT00702910	PHASE1	COMPLETED	A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients
NCT00711126	PHASE1	COMPLETED	A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection
NCT00783003	PHASE1	COMPLETED	A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
NCT00964249	PHASE1	COMPLETED	Phase I Study of GW642444M in Healthy Japanese Male Subjects
NCT01213849	PHASE1	COMPLETED	Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler
NCT01299558	PHASE1	COMPLETED	Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects
NCT01485445	PHASE1	COMPLETED	Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination
NCT01521377	PHASE1	COMPLETED	QTc Study GSK573719+GW642444
NCT01571999	PHASE1	COMPLETED	Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment
NCT01577680	PHASE1	COMPLETED	A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers
NCT01711463	PHASE1	COMPLETED	Relovair PD PK in Chinese Healthy Subjects
NCT06066606	Not specified	RECRUITING	U-LABA/ICS Effects on Exercise Performance, Vilanterol
NCT06077019	Not specified	RECRUITING	Role of Lung Function for Exercise Capacity in Well-trained Individuals
NCT03979807	Not specified	COMPLETED	A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT05127304	Not specified	COMPLETED	A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
NCT07541378	Not specified	SUSPENDED	Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

188 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
OLODATEROL	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRB2
ACEBUTOLOL	ChEMBL	Phase 4 (approved)	ADRB2
ADENOSINE	ChEMBL	Phase 4 (approved)	ADRB2
ALBUTEROL	ChEMBL	Phase 4 (approved)	ADRB2
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRB2
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRB2
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRB2
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
ATENOLOL	ChEMBL	Phase 4 (approved)	ADRB2
BENPERIDOL	ChEMBL	Phase 4 (approved)	ADRB2
BETAXOLOL	ChEMBL	Phase 4 (approved)	ADRB2
BISOPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRB2
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	ADRB2
CARTEOLOL	ChEMBL	Phase 4 (approved)	ADRB2
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRB2
CELIPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	ADRB2
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRB2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRB2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
CLOZAPINE	ChEMBL	Phase 4 (approved)	ADRB2
DARIFENACIN	ChEMBL	Phase 4 (approved)	ADRB2
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	ADRB2
DIPIVEFRIN	ChEMBL	Phase 4 (approved)	ADRB2
DOBUTAMINE	ChEMBL	Phase 4 (approved)	ADRB2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRB2
DOPAMINE	ChEMBL	Phase 4 (approved)	ADRB2
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRB2
ELAGOLIX	ChEMBL	Phase 4 (approved)	ADRB2
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
EPINEPHRINE BITARTRATE	ChEMBL	Phase 4 (approved)	ADRB2
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRB2
ESMOLOL	ChEMBL	Phase 4 (approved)	ADRB2
FENOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	ADRB2
FORMOTEROL	ChEMBL	Phase 4 (approved)	ADRB2
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRB2
INDACATEROL	ChEMBL	Phase 4 (approved)	ADRB2
ISOETHARINE	ChEMBL	Phase 4 (approved)	ADRB2
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	ADRB2
LABETALOL	ChEMBL	Phase 4 (approved)	ADRB2
LEVOBUNOLOL	ChEMBL	Phase 4 (approved)	ADRB2
LEVOSALBUTAMOL	ChEMBL	Phase 4 (approved)	ADRB2
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	ADRB2
LOPERAMIDE	ChEMBL	Phase 4 (approved)	ADRB2
LOXAPINE	ChEMBL	Phase 4 (approved)	ADRB2
MEBEVERINE	ChEMBL	Phase 4 (approved)	ADRB2
METAPROTERENOL	ChEMBL	Phase 4 (approved)	ADRB2
METOPROLOL	ChEMBL	Phase 4 (approved)	ADRB2
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	ADRB2
MONTELUKAST	ChEMBL	Phase 4 (approved)	ADRB2
NADOLOL	ChEMBL	Phase 4 (approved)	ADRB2
NEBIVOLOL	ChEMBL	Phase 4 (approved)	ADRB2
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	ADRB2
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRB2
OLANZAPINE	ChEMBL	Phase 4 (approved)	ADRB2
OXPRENOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PAROXETINE	ChEMBL	Phase 4 (approved)	ADRB2
PERPHENAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PHENYLEPHRINE	ChEMBL	Phase 4 (approved)	ADRB2
PIMAVANSERIN	ChEMBL	Phase 4 (approved)	ADRB2
PIMOZIDE	ChEMBL	Phase 4 (approved)	ADRB2
PINDOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PRACTOLOL	ChEMBL	Phase 4 (approved)	ADRB2
PRENYLAMINE	ChEMBL	Phase 4 (approved)	ADRB2
PRIMAQUINE	ChEMBL	Phase 4 (approved)	ADRB2
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRB2
PROPAFENONE	ChEMBL	Phase 4 (approved)	ADRB2
PROPRANOLOL	ChEMBL	Phase 4 (approved)	ADRB2
RANOLAZINE	ChEMBL	Phase 4 (approved)	ADRB2
REBOXETINE	ChEMBL	Phase 4 (approved)	ADRB2
RIBOFLAVIN 5’-PHOSPHATE	ChEMBL	Phase 4 (approved)	ADRB2
RIFAMPIN	ChEMBL	Phase 4 (approved)	ADRB2
RIFAXIMIN	ChEMBL	Phase 4 (approved)	ADRB2
RIMEGEPANT	ChEMBL	Phase 4 (approved)	ADRB2
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRB2
RITODRINE	ChEMBL	Phase 4 (approved)	ADRB2
SALMETEROL	ChEMBL	Phase 4 (approved)	ADRB2
SALMETEROL XINAFOATE	ChEMBL	Phase 4 (approved)	ADRB2
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRB2
SOTALOL	ChEMBL	Phase 4 (approved)	ADRB2
SUNITINIB	ChEMBL	Phase 4 (approved)	ADRB2
TAMOXIFEN	ChEMBL	Phase 4 (approved)	ADRB2
TAMSULOSIN	ChEMBL	Phase 4 (approved)	ADRB2
TEGASEROD	ChEMBL	Phase 4 (approved)	ADRB2
TERBUTALINE	ChEMBL	Phase 4 (approved)	ADRB2
THIORIDAZINE	ChEMBL	Phase 4 (approved)	ADRB2
TIMOLOL	ChEMBL	Phase 4 (approved)	ADRB2
TIOCONAZOLE	ChEMBL	Phase 4 (approved)	ADRB2
TOLTERODINE	ChEMBL	Phase 4 (approved)	ADRB2
TOLVAPTAN	ChEMBL	Phase 4 (approved)	ADRB2
VALDECOXIB	ChEMBL	Phase 4 (approved)	ADRB2